Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics

Iterum Therapeutics plc - Ordinary Share (ITRM): $0.66

0.06 (-8.33%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

ITRM Price/Volume Stats

Current price $0.66 52-week high $2.05
Prev. close $0.72 52-week low $0.60
Day low $0.65 Volume 25,300
Day high $0.72 Avg. volume 59,408
50-day MA $0.93 Dividend yield N/A
200-day MA $1.07 Market Cap 8.61M

ITRM Stock Price Chart Interactive Chart >


Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.


ITRM Latest News Stream


Event/Time News Detail
Loading, please wait...

ITRM Latest Social Stream


Loading social stream, please wait...

View Full ITRM Social Stream

Latest ITRM News From Around the Web

Below are the latest news stories about ITERUM THERAPEUTICS PLC that investors may wish to consider to help them evaluate ITRM as an investment opportunity.

Q2 2023 Iterum Therapeutics PLC Earnings Call

Q2 2023 Iterum Therapeutics PLC Earnings Call

Yahoo | August 12, 2023

Iterum Therapeutics Reports Second Quarter 2023 Financial Results

--Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ----Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2023.

Yahoo | August 11, 2023

Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023

DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Friday, August 11, 2023. Management will h

Yahoo | August 4, 2023

Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%

Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.

Yahoo | June 27, 2023

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.

Yahoo | June 21, 2023

Read More 'ITRM' Stories Here

ITRM Price Returns

1-mo -25.84%
3-mo -35.92%
6-mo -33.68%
1-year -59.76%
3-year -93.23%
5-year -99.31%
YTD -21.43%
2022 -85.71%
2021 -60.38%
2020 -78.02%
2019 -10.18%
2018 N/A

Continue Researching ITRM

Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:

Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!